Morphic announces participation in 2022 jefferies london healthcare conference

Waltham, mass., nov. 09, 2022 (globe newswire) -- morphic therapeutic (nasdaq: morf), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that dr. bruce rogers, president of morphic, will participate in a fireside chat at the jefferies london healthcare conference on wednesday, november 16th, at 10:55 am gmt.
MORF Ratings Summary
MORF Quant Ranking